Agrylin (Anagrelide Hydrochloride) - Current Clinical Trials

Agrylin Related Clinical Trials

Fed Study of Anagrelide Hydrochloride Capsules 1 mg to Agrylin® Capsules 1 mg [Completed]

Fasting Study of Anagrelide Hydrochloride Capsules 1 mg to Agrylin® Capsules 1 mg [Completed]

Anagrelide Retard vs. Placebo: Efficacy and Safety in "At-risk" Patients With Essential Thrombocythaemia [Recruiting]

A Phase II Study of the Pharmacokinetics of Anagrelide in Elderly and Young ET Patients [Recruiting]

A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients [Recruiting]

Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia [Recruiting]

French Observational Xagrid (FOX) Study In Adult Patients With Essential Thrombocythemia [Recruiting]

Safety and Pregnancy Outcomes in Thrombocythemia Patients Exposed to Xagrid Compared to Other Treatments [Recruiting]

Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Risk Essential Thrombocythaemia [Not yet recruiting]

Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: The RESPONSE Trial [Recruiting]

Nilotinib as First-Line Treatment of Ph+ CML in Early Chronic Phase [Recruiting]

HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET [Recruiting]